Santhera Pharmaceuticals (SIX: SANN)

Last close As at 05/08/2026

CHF14.94

0.88 (6.26%)

Market capitalisation

CHF234m

Santhera is a Swiss specialty pharmaceutical company focused on the development and commercialisation of therapies for rare diseases with high unmet medical need. Its lead product, AGAMREE (vamorolone), is an approved treatment for Duchenne muscular dystrophy and is being rolled out globally through a combination of direct commercialisation and strategic licensing partnerships.

Latest Insights

Market Data

Share Price CHF14.94
Market Cap CHF234m
52-Week High CHF18.84
52-Week Low CHF9.38
% Change 1M 0.8
% Change 6M 18.2
% Change 12M 5.1
Ave. Daily Volume 1yr 79,934

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Director, healthcare

Key Management

  • Dario Eklund

    CEO

  • Catherine Isted

    CFO

Share Price Chart

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.